Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
29 Agosto 2023 - 8:00AM
Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral
presentation and five posters across its development programs will
be included at the Society for the Study of Inborn Errors of
Metabolism (SSIEM) Annual Symposium 2023, being held August 29 –
September 1, 2023 in Jerusalem, Israel.
Oral Presentation:
Pompe Disease:
Abstract Title: Switching
treatment from alglucosidase alfa to cipaglucosidase alfa plus
miglustat positively affects motor function and quality of life in
patients with late-onset Pompe disease
- Presenter: Priya
Kishnani, MD, MBBS, Duke University Medical Center, Durham, NC,
U.S.A.
- Session: Clinical
Studies & Outcomes I
- Date and time:
Wednesday, August 30, 8:45-9:00 a.m. I.D.T.
- Location: Oren
2
Poster Sessions:
Fabry Disease:
Abstract Title: Multiorgan
involvement in females with Fabry disease: results from two phase
III trials and the followME registry (Poster #B169)
- Presenter: Peter
Nordbeck, MD, University Hospital Würzburg, Würzburg, Germany
- Location: Exhibit
Hall
Abstract Title: Exploring the
Experiences of Females Living with Fabry Disease in Canada (Poster
#B12)
- Presenter: Julia
Alton, Executive Director, Canadian Fabry Association, Ontario,
Canada
- Location: Exhibit
Hall
Pompe Disease:
Abstract Title: 104-week
efficacy and safety of cipaglucosidase alfa plus miglustat in
patients with late-onset Pompe disease previously treated with
alglucosidase alfa (Poster #B167)
- Presenter: Tahseen
Mozaffar, MD, Department of Neurology, University of California,
Irvine, CA, U.S.A.
- Location: Exhibit
Hall
Abstract Title: Safety of home
administration of cipaglucosidase alfa plus miglustat in late-onset
Pompe disease: results from multiple clinical trials (Poster
#B20)
- Presenter: Ozlem
Goker-Alpan, MD, Lysosomal and Rare Disorders Research and
Treatment Center, Fairfax, VA, U.S.A
- Location: Exhibit
Hall
Abstract Title: Effect size
analysis of cipaglucosidase alfa plus miglustat versus
alglucosidase alfa in ERT-experienced adults with late-onset Pompe
disease in PROPEL (Poster #B168)
- Presenter: Tahseen
Mozaffar, MD, Department of Neurology, University of California,
Irvine, CA, U.S.A.
- Location: Exhibit
Hall
For more information on the SSIEM Annual
Symposium 2023, please visit ssiem2023.org.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
diseases. With extraordinary patient focus, Amicus Therapeutics is
committed to advancing and expanding a pipeline of cutting-edge,
first- or best-in-class medicines for rare diseases. For more
information please visit the company’s website at www.amicusrx.com,
and follow on Twitter and LinkedIn.
CONTACTS:
Investors: Amicus Therapeutics Andrew
FaughnanVice President, Investor
Relationsafaughnan@amicusrx.com(609) 662-3809
Media: Amicus Therapeutics Diana Moore Head of
Global Corporate Communicationsdmoore@amicusrx.com(609)
662-5079
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Amicus Therapeutics (NASDAQ:FOLD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024